Evaluation of Efficacy and Safety of Gynomax® XL Ovule

Inclusion Criteria:

• Female patients with age ≥ 18 and ≤ 45 years

• Patients requiring treatment for bacterial vaginosis, candidal vulvovaginitis or mixedinfections according to the investigator's decision

• Signed informed consent

Exclusion Criteria:

• Known hypersensitivity to active ingredients of the study medications

• Vaginismus, endometriosis, dyspareunia

• Detection of urinary tract infection in urinalysis

• Acute or chronic infections such as pancreatitis, hypertriglyceridemia, liverdiseases, benign or malign tumors

• Usage of herbal medicines that interfere with microsomal enzymes, especiallycytochrome P450 (phenytoin, phenobarbital, primidone, carbamazepine, rifampicin,topiramate, felbamate, griseofulvin, HIV protease inhibitors such as ritonavir,nucleoside reverse transcriptase inhibitors such as efavirenz)

• History of cardiovascular event

• Advanced hypertension and diabetes

• Presence or known risk or of venous or arterial thromboembolism

• Undiagnosed abnormal vaginal bleeding, bleeding disorders, genital tumors

• Use of drugs containing ombitasvir / paritaprevir / ritonavir or dasabuvir during ortwo weeks before initiation of the study

• Pregnancy and/or breastfeeding

• Participation in any other trial 30 days before initiation of the study

• Postmenopausal women

• Abuse of alcohol

• Usage of medications containing acenocoumarol, anisindione, dicoumarol, phenindione,phenprocoumon, warfarin, cholestyramine, cimetidine, cyclosporine, disulfiram,fluorouracil, fosphenitoin, ketoconazole, lithium, rifampin, tacrolimus or propranolol

• Presence of a sexually transmitted disease such as syphilis, gonorrhea, etc. accordingto the investigators decision